The cellular microenvironment: a new target in the search for cellular and molecular treatment for Dupuytren’s disease

Bibliography

• Bissell MJ, Hall HG, Parry G. How does the extracellular matrix direct gene expression? J Theor Biol 1982;99(1):31-68
   PubMed Web of Science ®Google Scholar
• Boudreau N, Bissell MJ. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr Opin Cell Biol 1998;10(5):640-6
   PubMed Web of Science ®Google Scholar
• Bissell MJ, Radisky DC, Rizki A, et al. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 2002;70(9-10):537-46
   PubMed Web of Science ®Google Scholar
• Dupuytren G. Permanent retraction of the fingers, produced by an affection of the palmar fascia. Lancet 1834;2:222-5
   Google Scholar
• Dibenedetti DB, Nguyen D, Zografos L, et al. Prevalence, incidence, and treatments of Dupuytren’s disease in the United States: results from a population-based study. Hand (N Y) 2012;6(2):149-58
   Google Scholar
• Degreef I, De Smet L. A high prevalence of Dupuytren’s disease in Flanders. Acta Orthop Belg 2012;76(3):316-20
   Google Scholar
• Iwasaki H, Muller H, Stutte HJ, Brennscheidt U. Palmar fibromatosis (Dupuytren’s contracture). Ultrastructural and enzyme histochemical studies of 43 cases. Virchows Arch A Pathol Anat Histopathol 1984;405(1):41-53
   Google Scholar
• Tomasek JJ, Schultz RJ, Episalla CW, Newman SA. The cytoskeleton and extracellular matrix of the Dupuytren’s disease "myofibroblast": an immunofluorescence study of a nonmuscle cell type. J Hand Surg [Am] 1986;11(3):365-71
   Google Scholar
• Berndt A, Kosmehl H, Katenkamp D, Tauchmann V. Appearance of the myofibroblastic phenotype in Dupuytren’s disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. Pathobiology 1994;62(2):55-8
   Google Scholar
• Magro G, Fraggetta F, Colombatti A, Lanzafame S. Myofibroblasts and extracellular matrix glycoproteins in palmar fibromatosis. Gen Diagn Pathol 1997;142(3-4):185-90
   Google Scholar
• Bisson MA, McGrouther DA, Mudera V, Grobbelaar AO. The different characteristics of Dupuytren’s disease fibroblasts derived from either nodule or cord: expression of alpha-smooth muscle actin and the response to stimulation by TGF-beta1. J Hand Surg [Br] 2003;28(4):351-6
   Google Scholar
• Vi L, Gan BS, O’Gorman DB. The potential roles of cell migration and extra-cellular matrix interactions in Dupuytren’s disease progression and recurrence. Med Hypotheses 2010;74(3):510-12
   PubMed Web of Science ®Google Scholar
• Chiu HF, McFarlane RM. Pathogenesis of Dupuytren’s contracture: a correlative clinical- pathological study. J Hand Surg [Am] 1978;3(1):1-10
   PubMedGoogle Scholar
• Rayan GM. Clinical presentation and types of Dupuytren’s disease. Hand Clin 1999;15(1):87-96; vii
   Google Scholar
• Tomasek JJ, Schultz RJ, Haaksma CJ. Extracellular matrix-cytoskeletal connections at the surface of the specialized contractile fibroblast (myofibroblast) in Dupuytren disease. J Bone Joint Surg [Am] 1987;69(9):1400-7
   Google Scholar
• Badalamente MA, Sampson SP, Hurst LC, et al. The role of transforming growth factor beta in Dupuytren’s disease. J Hand Surg [Am] 1996;21(2):210-15
   PubMed Web of Science ®Google Scholar
• Wilbrand S, Ekbom A, Gerdin B. The sex ratio and rate of reoperation for Dupuytren’s contracture in men and women. J Hand Surg [Br] 1999;24(4):456-9
   PubMedGoogle Scholar
• Urban M, Feldberg L, Janssen A, Elliot D. Dupuytren’s disease in children. J Hand Surg [Br] 1996;21(1):112-16
   Google Scholar
• Saboeiro AP, Porkorny JJ, Shehadi SI, et al. Racial distribution of Dupuytren’s disease in Department of Veterans Affairs patients. Plast Reconstr Surg 2000;106(1):71-5
   Google Scholar
• Saar JD, Grothaus PC. Dupuytren’s disease: an overview. Plast Reconstr Surg 2000;106(1):125-34; quiz 135-126
   Google Scholar
• Gudmundsson KG, Arngrimsson R, Sigfusson N, et al. Epidemiology of Dupuytren’s disease: clinical, serological, and social assessment. The Reykjavik Study. J Clin Epidemiol 2000;53(3):291-6
   PubMed Web of Science ®Google Scholar
• Hindocha S, John S, Stanley JK, et al. The heritability of Dupuytren’s disease: familial aggregation and its clinical significance. J Hand Surg [Am] 2006;31(2):204-10
   Google Scholar
• O’Gorman D B, Vi L, Gan BS. Molecular mechanisms and treatment strategies for Dupuytren’s disease. Therapeutics and Clinical Risk Management 2010;6:383-90
   PubMed Web of Science ®Google Scholar
• Degreef I, De Smet L. Dupuytren’s disease: a predominant reason for elective finger amputation in adults. Acta Chir Belg 2009;109(4):494-7
   Web of Science ®Google Scholar
• Forsman M, Paakkonen V, Tjaderhane L, et al. The expression of myoglobin and ROR2 protein in Dupuytren’s disease. J Surg Res 2008;146(2):271-5
   Google Scholar
• McFarlane RM. Dupuytren’s disease: relation to work and injury. J Hand Surg [Am] 1991;16(5):775-9
   Google Scholar
• Elliot D, Ragoowansi R. Dupuytren’s disease secondary to acute injury, infection or operation distal to the elbow in the ipsilateral upper limb–a historical review. J Hand Surg [Br] 2005;30(2):148-56
   Google Scholar
• Logan AJ, Mason G, Dias J, Makwana N. Can rock climbing lead to Dupuytren’s disease? Br J Sports Med 2005;39(9):639-44
   Web of Science ®Google Scholar
• Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren’s disease. J Bone Joint Surg [Br] 1984;66(3):322-5
   PubMedGoogle Scholar
• Hart MG, Hooper G. Clinical associations of Dupuytren’s disease. Postgrad Med J 2005;81(957):425-8
   Google Scholar
• Geoghegan JM, Forbes J, Clark DI, et al. Dupuytren’s disease risk factors. J Hand Surg [Br] 2004;29(5):423-6
   Google Scholar
• Cagliero E, Apruzzese W, Perlmutter GS, Nathan DM. Musculoskeletal disorders of the hand and shoulder in patients with diabetes mellitus. Am J Med 2002;112(6):487-90
   PubMed Web of Science ®Google Scholar
• Arkkila PE, Kantola IM, Viikari JS. Dupuytren’s disease: association with chronic diabetic complications. J Rheumatol 1997;24(1):153-9
   Google Scholar
• Arkkila PE, Kantola IM, Viikari JS, et al. Dupuytren’s disease in type 1 diabetic patients: a five-year prospective study. Clin Exp Rheumatol 1996;14(1):59-65
   Google Scholar
• Ravindran Rajendran S, Bhansali A, Walia R, et al. Prevalence and pattern of hand soft-tissue changes in type 2 diabetes mellitus. Diabetes Metab 2012;37(4):312-17
   Google Scholar
• Redmond CL, Bain GI, Laslett LL, McNeil JD. Hand syndromes associated with diabetes: impairments and obesity predict disability. J Rheumatol 2009;36(12):2766-71
   PubMed Web of Science ®Google Scholar
• Cederlund RI, Thomsen N, Thrainsdottir S, et al. Hand disorders, hand function, and activities of daily living in elderly men with type 2 diabetes. J Diabetes Complications 2009;23(1):32-9
   Google Scholar
• Savas S, Koroglu BK, Koyuncuoglu HR, et al. The effects of the diabetes related soft tissue hand lesions and the reduced hand strength on functional disability of hand in type 2 diabetic patients. Diabetes Res Clin Pract 2007;77(1):77-83
   PubMed Web of Science ®Google Scholar
• Akyol A, Kiylioglu N, Copcu E, et al. Is diabetes mellitus type 2 a risk factor for Dupuytren’s contracture in the Mediterranean region? Plast Reconstr Surg 2006;117(6):2105-6
   Google Scholar
• Howard JC, Varallo VM, Ross DC, et al. Wound healing-associated proteins Hsp47 and fibronectin are elevated in Dupuytren’s contracture. J Surg Res 2004;117(2):232-8
   PubMed Web of Science ®Google Scholar
• Varallo VM, Gan BS, Seney S, et al. Beta-catenin expression in Dupuytren’s disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene 2003;22(24):3680-4
   Web of Science ®Google Scholar
• Howard JC, Varallo VM, Ross DC, et al. Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren’s disease cells are regulated by tension in vitro. BMC Musculoskelet Disord 2003;4:16
   PubMed Web of Science ®Google Scholar
• Bottomly D, Kyler SL, McWeeney SK, Yochum GS. Identification of {beta}-catenin binding regions in colon cancer cells using ChIP-Seq. Nucleic Acids Res 2010;38(17):5735-45
   Google Scholar
• Barker N, Morin PJ, Clevers H. The Yin-Yang of TCF/beta-catenin signaling. Adv Cancer Res 2000;77:1-24
   PubMedGoogle Scholar
• Shih IM, Yu J, He TC, et al. The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res 2000;60(6):1671-6
   Google Scholar
• Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58(6):1130-4
   PubMed Web of Science ®Google Scholar
• D’Amico M, Hulit J, Amanatullah DF, et al. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem 2000;275(42):32649-57
   Google Scholar
• Cheon SS, Nadesan P, Poon R, Alman BA. Growth factors regulate beta-catenin-mediated TCF-dependent transcriptional activation in fibroblasts during the proliferative phase of wound healing. Exp Cell Res 2004;293(2):267-74
   PubMed Web of Science ®Google Scholar
• Barker N, Clevers H. Catenins, Wnt signaling and cancer. Bioessays 2000;22(11):961-5
   Google Scholar
• Morin PJ. beta-catenin signaling and cancer. Bioessays 1999;21(12):1021-30
   Google Scholar
• Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398(6726):422-6
   PubMed Web of Science ®Google Scholar
• Caraci F, Gili E, Calafiore M, et al. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res 2008;57(4):274-82
   PubMed Web of Science ®Google Scholar
• Liu L, Carron B, Yee HT, et al. Wnt pathway in pulmonary fibrosis in the bleomycin mouse model. J Environ Pathol Toxicol Oncol 2009;28(2):99-108
   Google Scholar
• Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007;45(5):1298-305
   PubMed Web of Science ®Google Scholar
• Jiang F, Parsons CJ, Stefanovic B. Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J Hepatol 2006;45(3):401-9
   PubMed Web of Science ®Google Scholar
• Surendran K, McCaul SP, Simon TC. A role for Wnt-4 in renal fibrosis. Am J Physiol Renal Physiol 2002;282(3):F431-41
   Google Scholar
• He W, Dai C, Li Y, et al. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009;20(4):765-76
   PubMed Web of Science ®Google Scholar
• Hwang I, Seo EY, Ha H. Wnt/beta-catenin signaling: a novel target for therapeutic intervention of fibrotic kidney disease. Arch Pharm Res 2009;32(12):1653-62
   Google Scholar
• Letamendia A, Labbe E, Attisano L. Transcriptional regulation by Smads: crosstalk between the TGF-beta and Wnt pathways. J Bone Joint Surg Am 2001. 83-A Suppl 1(Pt 1):S31-9
   Google Scholar
• Rhee J, Ryu JH, Kim JH, et al. alpha-Catenin inhibits beta-catenin-T-cell factor/lymphoid enhancing factor transcriptional activity and collagen type II expression in articular chondrocytes through formation of Gli3R.alpha-catenin.beta-catenin ternary complex. J Biol Chem 2012;287(15):11751-60
   PubMed Web of Science ®Google Scholar
• Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999;18(47):6615-20
   PubMed Web of Science ®Google Scholar
• Couture J, Mitri A, Lagace R, et al. A germline mutation at the extreme 3’ end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of beta- catenin in the desmoid tumor. Clin Genet 2000;57(3):205-12
   Google Scholar
• Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function in aggressive fibromatosis (desmoid tumor). Am J Pathol 1998;153(3):709-14
   PubMed Web of Science ®Google Scholar
• Mann B, Gelos M, Siedow A, et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999;96(4):1603-8
   PubMed Web of Science ®Google Scholar
• Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275(5307):1787-90
   PubMed Web of Science ®Google Scholar
• Dolmans GH, Werker PM, Hennies HC, et al. Wnt signaling and Dupuytren’s disease. N Engl J Med 2011;365(4):307-17
   PubMed Web of Science ®Google Scholar
• O’Gorman DB, Wu Y, Seney S, et al. Wnt expression is not correlated with beta-catenin dysregulation in Dupuytren’s Disease. J Negat Results Biomed 2006;5(1):13
   Google Scholar
• Bowley E, O’Gorman DB, Gan BS. Beta-catenin signaling in fibroproliferative disease. J Surg Res 2007;138(1):141-50
   PubMed Web of Science ®Google Scholar
• Hu FZ, Nystrom A, Ahmed A, et al. Mapping of an autosomal dominant gene for Dupuytren’s contracture to chromosome 16q in a Swedish family. Clin Genet 2005;68(5):424-9
   PubMed Web of Science ®Google Scholar
• Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci USA 2000;97(22):12103-8
   Google Scholar
• Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001;20(2):252-9
   PubMed Web of Science ®Google Scholar
• Morali OG, Delmas V, Moore R, et al. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001;20(36):4942-50
   Web of Science ®Google Scholar
• Kuemmerle JF. Endogenous IGF-I protects human intestinal smooth muscle cells from apoptosis by regulation of GSK-3 beta activity. Am J Physiol Gastrointest Liver Physiol 2005;288(1):G101-10
   Google Scholar
• Behrens J. Cross-regulation of the Wnt signalling pathway: a role of MAP kinases. J Cell Sci 2000;113(Pt 6):911-19
   Google Scholar
• Cheon SS, Wei Q, Gurung A, et al. Beta-catenin regulates wound size and mediates the effect of TGF-beta in cutaneous healing. Faseb J 2006;20(6):692-701
   PubMed Web of Science ®Google Scholar
• Wang H, Rajan S, Liu G, Chakrabarty S. Transforming growth factor beta suppresses beta-catenin/Wnt signaling and stimulates an adhesion response in human colon carcinoma cells in a Smad4/DPC4 independent manner. Cancer Lett 2008;264(2):281-7
   Google Scholar
• Novak A, Hsu SC, Leung-Hagesteijn C, et al. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sci USA 1998;95(8):4374-9
   PubMed Web of Science ®Google Scholar
• Palsgaard J, Emanuelli B, Winnay JN, et al. Cross-talk between insulin and Wnt signaling in preadipocytes: role of Wnt co-receptor low density lipoprotein receptor-related protein-5 (LRP5). J Biol Chem 2012;287(15):12016-26
   Google Scholar
• Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: wnt you like to know? Endocr Rev 2005;26(7):898-915
   Google Scholar
• Easwaran V, Pishvaian M. Salimuddin, Byers S. Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr Biol 1999;9(23):1415-18
   Google Scholar
• Verjee LS, Verhoekx JS, Chan JK, et al. Unraveling the signaling pathways promoting fibrosis in Dupuytren’s disease reveals TNF as a therapeutic target. Proc Natl Acad Sci USA 2013;110(10):E928-37
   PubMed Web of Science ®Google Scholar
• Rooney B, O’Donovan H, Gaffney A, et al. CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett 2012;585(3):531-8
   Google Scholar
• Baird KS, Crossan JF, Ralston SH. Abnormal growth factor and cytokine expression in Dupuytren’s contracture. J Clin Pathol 1993;46(5):425-8
   PubMed Web of Science ®Google Scholar
• Berndt A, Kosmehl H, Mandel U, et al. TGF beta and bFGF synthesis and localization in Dupuytren’s disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J 1995;27(12):1014-20
   Google Scholar
• Bayat A, Watson JS, Stanley JK, et al. Genetic susceptibility in Dupuytren’s disease. TGF-beta1 polymorphisms and Dupuytren’s disease. J Bone Joint Surg Br 2002;84(2):211-15
   PubMedGoogle Scholar
• Kraljevic Pavelic S, Sedic M, Hock K, et al. An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren’s disease. J Pathol 2009;217(4):524-33
   Google Scholar
• Raykha C, Crawford J, Gan BS, et al. IGF-II and IGFBP-6 regulate cellular contractility and proliferation in Dupuytren’s disease. Biochim Biophys Acta 2013;1832(10):1511-19
   PubMed Web of Science ®Google Scholar
• Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 2007;179(6):1311-23
   PubMed Web of Science ®Google Scholar
• Vi L, de Lasa C, DiGuglielmo GM, Dagnino L. Integrin-linked kinase is required for TGF-beta1 induction of dermal myofibroblast differentiation. J Invest Dermatol 2013;131(3):586-93
   Google Scholar
• Huang C, Ogawa R. Fibroproliferative disorders and their mechanobiology. Connect Tissue Res 2012;53(3):187-96
   PubMed Web of Science ®Google Scholar
• Iannone F, Lapadula G. The pathophysiology of osteoarthritis. Aging Clin Exp Res 2003;15(5):364-72
   Google Scholar
• Hyde C, Hollier B, Anderson A, et al. Insulin-like growth factors (IGF) and IGF-binding proteins bound to vitronectin enhance keratinocyte protein synthesis and migration. J Invest Dermatol 2004;122(5):1198-206
   PubMed Web of Science ®Google Scholar
• Noble A, Towne C, Chopin L, et al. Insulin-like growth factor-II bound to vitronectin enhances MCF-7 breast cancer cell migration. Endocrinology 2003;144(6):2417-24
   PubMed Web of Science ®Google Scholar
• Hollier BG, Kricker JA, Van Lonkhuyzen DR, et al. Substrate-bound insulin-like growth factor (IGF)-I-IGF binding protein-vitronectin-stimulated breast cell migration is enhanced by coactivation of the phosphatidylinositide 3-Kinase/AKT pathway by alphav-integrins and the IGF-I receptor. Endocrinology 2008;149(3):1075-90
   PubMed Web of Science ®Google Scholar
• Parker T, Upton Z, Leavesley D. Vitronectin modulates human mesenchymal stem cell response to insulin-like growth factor-I and transforming growth factor beta 1 in a serum-free environment. Tissue Eng Part A 2009;15(6):1415-26
   Google Scholar
• Nishida T, Kawaki H, Baxter RM, et al. CCN2 (Connective Tissue Growth Factor) is essential for extracellular matrix production and integrin signaling in chondrocytes. J Cell Commun Signal 2007;1(1):45-58
   Google Scholar
• Vi L, Njarlangattil A, Wu Y, et al. Type-1 collagen differentially alters beta-catenin accumulation in primary Dupuytren’s Disease cord and adjacent palmar fascia cells. BMC Musculoskelet Disord 2009;10(1):72
   Google Scholar
• Wipff PJ, Hinz B. Myofibroblasts work best under stress. J Bodyw Mov Ther 2009;13(2):121-7
   PubMedGoogle Scholar
• Satish L, Laframboise WA, O’Gorman DB, et al. Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren’s Contracture. BMC Med Genomics 2008;1:10
   Web of Science ®Google Scholar
• Satish L, LaFramboise WA, Johnson S, et al. Fibroblasts from phenotypically normal palmar fascia exhibit molecular profiles highly similar to fibroblasts from active disease in Dupuytren’s Contracture. BMC Med Genomics 2012;5:15
   Google Scholar
• Eaton C, Seegenschmiedt MH, Bayat A, et al. Primary Dupuytren‚ Äôs Disease Cell Interactions with the Extra-cellular Environment: a link to disease progression? Dupuytren‚ Äôs disease and related hyperproliferative disorders. Springer Berlin Heidelberg; p. 151-9
   Google Scholar
• Vi L, Gan BS, O’Gorman DB. The potential roles of cell migration and extra-cellular matrix interactions in Dupuytren’s disease progression and recurrence. Med Hypotheses 2011;74(3):510-12
   Google Scholar
• Hurst LC, Badalamente MA. Nonoperative treatment of Dupuytren’s disease. Hand Clin 1999;15(1):97-107. vii
   Google Scholar
• Foucher G, Medina J, Navarro R. Percutaneous needle aponeurotomy: complications and results. J Hand Surg [Br] 2003;28(5):427-31
   Google Scholar
• Badalamente MA, Hurst LC. Enzyme injection as nonsurgical treatment of Dupuytren’s disease. J Hand Surg [Am] 2000;25(4):629-36
   PubMed Web of Science ®Google Scholar
• Badalamente MA, Hurst LC, Hentz VR. Collagen as a clinical target: nonoperative treatment of Dupuytren’s disease. J Hand Surg [Am] 2002;27(5):788-98
   Google Scholar
• Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 2009;361(10):968-79
   PubMed Web of Science ®Google Scholar
• Hori YS, Kuno A, Hosoda R, et al. Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. J Pharmacol Exp Ther 2012;338(3):784-94
   Google Scholar
• Ji Q, Liu X, Fu X, et al. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/beta-catenin signal pathway. PLoS One 2013;8(11):e78700
   PubMed Web of Science ®Google Scholar
• Abed E, Couchourel D, Delalandre A, et al. Low sirtuin 1 levels in human osteoarthritis subchondral osteoblasts lead to abnormal sclerostin expression which decreases Wnt/beta-catenin activity. Bone 2014;59:28-36
   Google Scholar
• Tsai JH, Hsu LS, Lin CL, et al. 3,5,4’-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/beta-catenin signaling cascades and reversal of epithelial-mesenchymal transition. Toxicol Appl Pharmacol 2013;272(3):746-56
   PubMed Web of Science ®Google Scholar
• Chen HJ, Hsu LS, Shia YT, et al. The beta-catenin/TCF complex as a novel target of resveratrol in the Wnt/beta-catenin signaling pathway. Biochem Pharmacol 2012;84(9):1143-53
   Google Scholar
• Wang H, Zhou H, Zou Y, et al. Resveratrol modulates angiogenesis through the. GSK3beta/beta-catenin/TCF-dependent pathway in human endothelial cells. Biochem Pharmacol 2010;80(9):1386-95
   PubMed Web of Science ®Google Scholar
• Cedidi CC, Ingianni G. Compression therapy after complex soft tissue trauma, and flap coverage: optimization of scar development, swelling, function, and aesthetic result. Eur J Med Res 2006;11(2):85-9
   Google Scholar
• Wei J, Melichian D, Komura K, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum 2011;63(6):1707-17
   PubMedGoogle Scholar
• Borthwick LA, Wynn TA, Fisher AJ. Cytokine mediated tissue fibrosis. Biochim Biophys Acta 2013;1832(7):1049-60
   PubMed Web of Science ®Google Scholar